FAYETTEVILLE, Ark., March 5, 2026 /PRNewswire/ — HTA and Venture Atlas Labs announced a new commercial and clinical acceleration program that connects international health technology companies with ...

Hello, and thank you for standing by. At this time, I would like to welcome everyone to the CareDx Investor Webinar Call. [Operator Instructions] I would now like to turn the conference over to ...

Dr. Mazzone and colleagues report on a cell-free DNA fragmentome assay (DELFIscore) for the classification of lung cancer (1). We have concerns and recommendations. Study participants were enrolled ...

Hospitals are facing a steady rise in payment disputes over their assignment of a Diagnosis Related Group (DRG). These disputes fall into two general categories: coding-based DRG downgrades and ...

ABSTRACT: Microfluidic wearables move microliter biofluids across soft, low-impedance interfaces and into stable transducers on skin, enabling time-stamped chemistry without pumps. In this review ...

The field of infection research is at a transformative phase, where emerging infections, antimicrobial resistance, and technological advances necessitate the development of novel translational models ...

Health care leaders may want to keep a closer eye on clinical validation for artificial intelligence (AI)-enabled medical devices (AIMDs), based on a recent JAMA Health Forum study. The study examined ...

The integration of artificial intelligence (AI) in voice biomarker analysis presents a transformative opportunity for objective and non-invasive diagnostics in healthcare. However, clinical adoption ...

The LifeLeaf non-invasive glucose and blood sugar monitor. [Image from LifePlus] LifePlus today announced the clinical validation of its LifeLeaf non-invasive and cuffless wearable for continuous ...

Clinical outcomes of patients with stage I triple-negative breast cancer (TNBC) treated with or without chemotherapy: The Mayo Clinic experience. ATX evaluated across 5 cohorts individually and pooled ...

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announces the commencement of a ...